BTIG Research Issues Pessimistic Forecast for LifeMD (NASDAQ:LFMD) Stock Price

LifeMD (NASDAQ:LFMD) had its price target cut by research analysts at BTIG Research from $10.00 to $9.00 in a report issued on Thursday, MarketBeat.com reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective would indicate a potential upside of 152.81% from the company’s current price.

Other equities analysts have also issued research reports about the company. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research note on Tuesday, May 26th. Zacks Research lowered LifeMD from a “hold” rating to a “strong sell” rating in a report on Friday, July 17th. Wall Street Zen cut LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. UBS Group reaffirmed a “buy” rating on shares of LifeMD in a research note on Wednesday, May 27th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of LifeMD in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.57.

LifeMD Stock Performance

LFMD stock opened at $3.56 on Thursday. LifeMD has a 52 week low of $2.56 and a 52 week high of $7.32. The company has a market capitalization of $171.59 million, a PE ratio of -71.19 and a beta of 2.02. The company’s 50-day simple moving average is $4.39 and its 200 day simple moving average is $3.97.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The business had revenue of $47.28 million during the quarter, compared to analyst estimates of $49.16 million. LifeMD had a negative return on equity of 150.35% and a net margin of 0.10%. On average, analysts forecast that LifeMD will post -0.37 EPS for the current year.

Institutional Trading of LifeMD

Several institutional investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd acquired a new position in LifeMD during the 4th quarter worth about $36,000. R Squared Ltd acquired a new stake in shares of LifeMD in the first quarter valued at about $41,000. Jain Global LLC bought a new position in shares of LifeMD during the fourth quarter worth about $45,000. Quarry LP bought a new position in shares of LifeMD during the third quarter worth about $52,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after acquiring an additional 2,452 shares during the period. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.